| Tyler S Carroll, MD | |
|
10968 N Alpine Hwy, Highland, UT 84003-8874 | |
| (801) 763-2900 | |
| Not Available |
| Full Name | Tyler S Carroll |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 22 Years |
| Location | 10968 N Alpine Hwy, Highland, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518973643 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 53765521205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| American Fork Hospital | American fork, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
The Weizmann Institute of Science in Rehovot, Israel, today announced the installation of the Biospec® 15.2 Tesla USR™ preclinical ultra-high field magnetic resonance imaging (MRI) instrument from Bruker. The new instrument is installed in the Daniel Wolf building of the Department of Chemical Research, and is used by the MRI Biosensors laboratory, led by Dr. Bar-Shir, and the laboratory of Professor Neeman, to open new frontiers in molecular and microscopic imaging, adding to the team's existing world-class MRI instruments.
Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).
Researchers in Kobe, Japan, and Montreal, Canada, have uncovered a previously unknown mechanism which causes embryonic germ cells which later develop into sperm or ova to go through a period of "transcriptional silence," during which information from the cell's DNA cannot be copied.
In just the past few years, researchers have found a way to use a naturally occurring bacterial system known as CRISPR/Cas9 to inactivate or correct specific genes in any organism. CRISPR/Cas9 gene editing activity runs continuously, though, leading to risk of additional editing at unwanted sites. Now, researchers at University of California, San Diego School of Medicine, Ludwig Cancer Research and Isis Pharmaceuticals demonstrate a commercially feasible way to use RNA to turn the CRISPR-Cas9 system on and off as desired - permanently editing a gene, but only temporarily activating CRISPR-Cas9.
› Verified 2 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
The Weizmann Institute of Science in Rehovot, Israel, today announced the installation of the Biospec® 15.2 Tesla USR™ preclinical ultra-high field magnetic resonance imaging (MRI) instrument from Bruker. The new instrument is installed in the Daniel Wolf building of the Department of Chemical Research, and is used by the MRI Biosensors laboratory, led by Dr. Bar-Shir, and the laboratory of Professor Neeman, to open new frontiers in molecular and microscopic imaging, adding to the team's existing world-class MRI instruments.
Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).
Researchers in Kobe, Japan, and Montreal, Canada, have uncovered a previously unknown mechanism which causes embryonic germ cells which later develop into sperm or ova to go through a period of "transcriptional silence," during which information from the cell's DNA cannot be copied.
In just the past few years, researchers have found a way to use a naturally occurring bacterial system known as CRISPR/Cas9 to inactivate or correct specific genes in any organism. CRISPR/Cas9 gene editing activity runs continuously, though, leading to risk of additional editing at unwanted sites. Now, researchers at University of California, San Diego School of Medicine, Ludwig Cancer Research and Isis Pharmaceuticals demonstrate a commercially feasible way to use RNA to turn the CRISPR-Cas9 system on and off as desired - permanently editing a gene, but only temporarily activating CRISPR-Cas9.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tyler S Carroll, MD Po Box 27128, Salt Lake City, UT 84127-0128 Ph: (801) 763-2900 | Tyler S Carroll, MD 10968 N Alpine Hwy, Highland, UT 84003-8874 Ph: (801) 763-2900 |
News Archive
The Weizmann Institute of Science in Rehovot, Israel, today announced the installation of the Biospec® 15.2 Tesla USR™ preclinical ultra-high field magnetic resonance imaging (MRI) instrument from Bruker. The new instrument is installed in the Daniel Wolf building of the Department of Chemical Research, and is used by the MRI Biosensors laboratory, led by Dr. Bar-Shir, and the laboratory of Professor Neeman, to open new frontiers in molecular and microscopic imaging, adding to the team's existing world-class MRI instruments.
Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).
Researchers in Kobe, Japan, and Montreal, Canada, have uncovered a previously unknown mechanism which causes embryonic germ cells which later develop into sperm or ova to go through a period of "transcriptional silence," during which information from the cell's DNA cannot be copied.
In just the past few years, researchers have found a way to use a naturally occurring bacterial system known as CRISPR/Cas9 to inactivate or correct specific genes in any organism. CRISPR/Cas9 gene editing activity runs continuously, though, leading to risk of additional editing at unwanted sites. Now, researchers at University of California, San Diego School of Medicine, Ludwig Cancer Research and Isis Pharmaceuticals demonstrate a commercially feasible way to use RNA to turn the CRISPR-Cas9 system on and off as desired - permanently editing a gene, but only temporarily activating CRISPR-Cas9.
› Verified 2 days ago
Peter Michael Sundwall, Family Medicine Medicare: Medicare Enrolled Practice Location: 10290 N. North County Blvd. Ste 200, Highland, UT 84003 Phone: 208-625-6000 Fax: 208-625-6001 | |
Dr. Charles Wesley Walton, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 11286 N Tamarack Dr, Highland, UT 84003 Phone: 801-492-9162 Fax: 801-492-9163 | |
Robert W Slack, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10968 N Alpine Hwy, Highland, UT 84003 Phone: 801-763-2900 | |
Peter V Sundwall Jr., M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 10290 N North County Blvd, Suite 200, Highland, UT 84003 Phone: 801-899-3391 Fax: 801-685-3266 | |
Jeanne Marie Borget, APRN Family Medicine Medicare: Medicare Enrolled Practice Location: 10644 N 5660 W, Highland, UT 84003 Phone: 801-664-7679 | |
Terrance Stephen Drake, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5563 Coventry Rd, Highland, UT 84003 Phone: 801-216-4581 |